June 19th 2025
NIBRT, Firefinch, and eg technology will join the center, adding to its collective of healthcare innovators.
Paperless Reporting: How to Satisfy FDA
August 1st 2004Most, if not all, pharmaceutical companies today are moving towards a paperless reporting structure. This article examines FDA's 21 CFR Part 11 regulations, which relate to technical and procedural compliance for electronic records and signatures.
Asset Management Tools for Minimizing Regulatory Risk and Maximizing Efficiency
August 1st 2004Resolving the asset headache - the author explains how effective asset management can enable pharmaceutical companies to boost operational profit, increase production uptime and adhere to regulatory standards.
A New Definition for API Starting Materials
June 1st 2004The FDA guidelines that stipulate the conditions for starting materials are currently being superseded. PhRMA and several European pharmaceutical manufacturers have already added their voices to the ongoing discussion and, as this editorial explains, the debate is far from over. Rules are important, but industry is looking to a future when health care authorities are less inclined to impart total control over every aspect of production.
Validation and Compliance: Software Systems Prepare Manufacturers for Com(PAT)ibility
May 2nd 2004From data acquisition to enterprise resource planning, software systems operating at all levels of pharmaceutical manufacturing prepare for the seemingly inevitable implementation of process anlytical technology.
21 CFR Part 11 and Risk Assessment: Adapting Fundamental Methodologies to a Current Rule
May 1st 2004FDA expects a firm that is subject to GxP to develop a risk evaluation of its product and to then mitigate the identified risks. Identified risks may be addressed by technical fixes that effectively eliminate the risks or reduce the likelihood of occurrence and/or severity of consequences to acceptable levels.
Quality Systems for the 21st Century: Process Analytical Technology
March 1st 2004Following the launch of its initiative, "Pharmaceutical cGMPs for the 21st Century: A Risk-Based Approach," FDA has been looking to process analytical technology (PAT) for improvements in process efficiency and quality. This article discusses the implementation of PAT systems into production environments, its impact on quality assurance and the necessity of an integrated approach. Options for implementing PAT are also presented.